Compare MNSO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNSO | BEAM |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | 2020 | 2019 |
| Metric | MNSO | BEAM |
|---|---|---|
| Price | $12.21 | $25.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $26.20 | ★ $50.75 |
| AVG Volume (30 Days) | 671.6K | ★ 2.6M |
| Earning Date | 05-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $21.09 | N/A |
| Revenue Next Year | $15.43 | $33.77 |
| P/E Ratio | $20.04 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $11.12 | $15.60 |
| 52 Week High | $26.74 | $38.26 |
| Indicator | MNSO | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 30.23 |
| Support Level | $11.37 | $24.80 |
| Resistance Level | $12.25 | $33.32 |
| Average True Range (ATR) | 0.26 | 1.99 |
| MACD | 0.11 | -0.94 |
| Stochastic Oscillator | 45.48 | 1.83 |
MINISO Group Holding Ltd is a value retailer offering a variety of trendy lifestyle products featuring IP design. The principal activity of the Company is investment holding. The company's product categories include home decor, small electronics, textiles, accessories, beauty tools, toys, cosmetics, personal care, snacks, fragrance and perfumes, and stationery and gifts. Its segment includes the MINISO brand -Chinese Mainland and MINISO brand-Overseas which is engaged in the Design, buying, and sale of lifestyle products, and the TOP TOY brand, which is engaged in the Design, buying, and sale of pop toys. The company generates maximum revenue from theMINISO brand -Chinese Mainland segment. Geographically, it derives a majority of its revenue from Chinese Mainland.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.